Clinical trials: Lipemia
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Dyslipidemia
Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
The investigators propose to investigate if using a combination of medications that may improve cholesterol give additional benefit to that gained from the statin medication, Lipitor.
- Trial name
- CENTAUR (NCT00728910)
- Testing
- Atorvastatin, ABT335, ER Niacin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pennsylvania
Hypercholesterolemia
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use…
- Trial name
- FUTURA (NCT00526058)
- Testing
- Secura then Futura, Futura then Secura
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- B. Braun Medical Inc.
Hypercholesterolemia
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40).
- Trial name
- NCT00782184
- Testing
- ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg
- Volunteers
- 250 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is…
- Trial name
- NCT01592240
- Testing
- PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316)
- Where
- 74 sites in United States
- Volunteers
- 354 people
- Sponsor
- Pfizer
Ischemic Stroke
Japan Statin Treatment Against Recurrent Stroke (J-STARS)
Although hyperlipidemia is not always the risk factor of stroke, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can decrease the incidence of stroke in the patient with ischemic heart disease.
- Trial name
- NCT00221104
- Testing
- Pravastatin
- Where
- Japan
- Volunteers
- 1,578 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Stroke, TIA
Reducing Risk of Recurrence
Adults who have had a previous stroke or transient ischemic attack (TIA) remain at risk for having a second serious event, especially if they have uncontrolled blood pressure or cholesterol.
- Conditions
- Stroke, TIA, Hypertension, Hyperlipidemia
- Trial name
- RRR (NCT01122394)
- Testing
- TI, AP
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- VA Office of Research and Development
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
This was a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C).
- Trial name
- ORION-13 (NCT04659863)
- Testing
- Inclisiran
- Where
- 11 sites in United States, Canada and 6 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
HIV Infections, Hyperlipidemia
Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
Pravastatin (Pravachol) is approved by the Food and Drug Administration (FDA) and is used to treat high cholesterol. Darunavir (Prezista) and ritonavir (Norvir) are approved by the Food and Drug Administration (FDA) to treat HIV…
- Trial name
- NCT00630734
- Testing
- Pravastatin, Darunavir, Ritonavir
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hypercholesterolemia
Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study
This is a prospective, placebo-controlled, cross-over trial comparing the the effects of approximately 7 weeks of placebo treatment to 7 weeks of ezetimibe (10mg/day) treatment on several parameters of reverse cholesterol…
- Trial name
- NCT00701727
- Testing
- ezetimibe
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Radiant Research
Hypercholesterolemia
A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
The purpose of this study is to assess the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg versus placebo added to ongoing stable statin therapy or…
- Trial name
- NCT04784442
- Testing
- 180mg of ETC-1002(bempedoic acid), 120mg of ETC-1002(bempedoic acid), 60mg of ETC-1002(bempedoic acid)
- Where
- Japan
- Volunteers
- 188 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Hypercholesterolemia
Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)
This is a randomized, open label, parallel group comparison study. Following a 1-week screening period, patients will be randomized to 1 of 2 treatment groups: ezetimibe added to ongoing statin treatment (ezetimibe plus…
- Trial name
- NCT00652327
- Testing
- Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin), Double Statin (simvastatin, atorvastatin, or pravastatin)
- Volunteers
- 83 people
- Sponsor
- Organon and Co
Hypercholesterolemia
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)
The purpose of this study is to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin versus atorvastatin in hypercholesterolemic patients at moderately high risk for coronary heart disease not adequately…
- Trial name
- NCT00276458
- Testing
- Comparator: atorvastatin, Comparator: ezetimibe
- Volunteers
- 196 people
- Sponsor
- Organon and Co
Cardiovascular Disease, Hypertension
Unmet Social Needs Study
The impacts of unmet social needs, such as homelessness, inconsistent access to food, and exposure to violence on health are well-established, especially for cardiovascular disease.
- Conditions
- Cardiovascular Disease, Hypertension, Diabetes Mellitus, Hyperlipidemia
- Trial name
- NCT04977583
- Testing
- Unmet Need Screening, Unmet Need Referral - Resource Sheet, Unmet Need Referral Assistance
- Where
- 3 sites in United States
- Volunteers
- 479 people
- Sponsor
- VA Office of Research and Development
Cardiovascular Diseases
Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America
Post-Marketing Observational study of Niaspan® tablet in accordance with each country regulations. This study will be conducted in a prospective, single-arm, multi-center format.
- Trial name
- NCT01200160
- Testing
- Niacin
- Where
- 22 sites in Colombia, Mexico and 1 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Abbott
Hypercholesterolemia, Coronary Disease
The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)
This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe/simvastatin 10/20 mg when administered daily versus doubling the dose of simvastatin to 40 mg in patients with hypercholesterolemia and…
- Trial name
- NCT00423579
- Testing
- Ezetimibe/Simvastatin 10/20 mg, simvastatin 40 mg
- Volunteers
- 120 people
- Sponsor
- Organon and Co
HIV Infection, Hyperlipidemia
Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study
The purpose of this study is to evaluate the change in brachial artery reactivity in HIV-infected subjects with elevated lipid levels who are switched to an atazanavir containing antiretroviral regimen
- Trial name
- SABAR (NCT00225017)
- Testing
- Atazanavir, current antiretroviral regimen
- Where
- 7 sites in United States, Argentina and 1 more
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Hyperlipoproteinemia Type II, Hypercholesterolemia, Familial
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
The objective of this study is to evaluate the efficacy and tolerability of adding anacetrapib to ongoing statin therapy in participants with heterozygous familial hypercholesterolemia (HeFH).
- Trial name
- REALIZE (NCT01524289)
- Testing
- Anacetrapib
- Volunteers
- 306 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertriglyceridemia, Hyperglycemia
Intravenous Fat Emulsions and Premature Infants
The purpose of this study is to study the tolerances of Extremely Low Birthweight Infants who are born at less than 750 grams who are started at a higher infusion rate of intravenous lipid emulsions (2 gm/kg/day).
- Trial name
- NCT01096446
- Testing
- Intravenous Fat Emulsions
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OSF Healthcare System
Severe Familial Hypercholesterolemia
Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
A study to assess the long term safety and tolerability of evolocumab (AMG 145) in adolescents and adults with severe familial hypercholesterolemia.
- Trial name
- TAUSSIG (NCT01624142)
- Testing
- Evolocumab
- Where
- 44 sites in United States, Australia and 16 more
- Volunteers
- 300 people
- Sponsor
- Amgen